LATEST FROM THE BLOG:
2020 is in the rearview mirror as the year no one was prepared for. During COVID, Prelude to a Cure (Prelude/P2AC) found itself at odds with our mission and goal with the need to be safe and socially distant from each other. Though, we were not idle. The Board of Prelude took a look at ourselves and realized we had room for improvement to redefine ourselves so that you know exactly who we are, what we do, how to get involved, give and see the research we’ve funded.
Prelude began 8 years ago with the determination to provide critical funding for the least funded of the major cancers; lung cancer. Our focus remains unique in that our purpose to provide “seed grants” for young investigators is more vital and in demand. These ideas at their emergent stage become the new ideas that can grow into world changing discoveries. For you; our family, friends, donors, supporters, patients/survivors and caregivers it means that together, we have work to do. Yes, we’re the elephant in the room, the one cancer that evokes many strong emotions and reactions which have become a part of our unconscious bias.Read more…
Our Twitter feed
Whether you’re a researcher, a nurse, a CPA, a pro golfer, or anything else, YOU are part of finding a cure for lung cancer. We would like you to join us. Your contribution can be through science, funding, or participation. Learn more at https://t.co/wCMZ430mUk. #Tampa #StPete https://t.co/q0purBXioQ
Raising money for innovative lung cancer research. That’s the Prelude to a Cure mission. We’re proud to share some of the results of the research we’ve funded, as well as some of the ongoing studies made possible by our generous supporters: https://t.co/T1AlFNoBOl. https://t.co/ATODs9NlSn
In an interview OncLive®, Jacob Sands, MD, a physician at Dana-Farber Cancer Institute, and an instructor in medicine at Harvard Medical School, discussed current approaches to the treatment of patients with early-stage and locally advanced NSCLC. https://t.co/ilX1rYZiKb